Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netakimab in Children With Moderate to Severe Plaque Psoriasis
NCT06640517Phase 3Active, not recruiting
- Sponsor
- BIOCAD
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of netakimab in plaque psoriasis (3 arms), sponsored by BIOCAD. Primary endpoints: Proportion of subjects achieving 75% reduction in Psoriasis Area and Severity Index at 12 weeks and Proportion of subjects achieving static Physician's Global Assessment score of 0 or 1 at 12 weeks. Started Aug 2024; status: active, not recruiting.
02
Drugs
netakimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06640517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640517.